The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities
The Trust’s shift from single-use compostable cups to a reusable system was driven by the need to reduce environmental impact and control long-term costs
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
Subscribe To Our Newsletter & Stay Updated
